Bispecific Antibody Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Epcoritamab is for patients who have received two or more lines of systemic therapy
Source: medpagetoday.com
📰 Tycel Phillips News
Page 3 - Tycel Phillips News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tycel Phillips. Real-time updates on events, politics, business and more.
FDA Approves Epkinly for Relapsed/Refractory DLBCL
The FDA approval of Epkinly also includes a subset of patients with indolent lymphoma-related DLBCL and those with high-grade B-cell lymphoma after two or more systemic therapies.
United States Meghan Gutierrez Tycel Phillips Drug Administration Lymphoma Research Foundation Boxed Warning
Source: curetoday.com
City of Hope researchers present innovative studies at American Society of Hematology (ASH) Annual Meeting
/PRNewswire/ -- Doctors and scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, presented data...
Source: prnewswire.com
Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody
Most complete responses lasted 24 months or longer after limited-duration glofitamab
Ann Arbor United States Tycel Phillips Charles Bankhead Martin Hutchings American Society Of Hematology
Source: medpagetoday.com
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted as oral presentations at the 63rd American Society of Hematology Annual
Source: finanznachrichten.de